Actualités



Retour


10/09/2019
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
Pharvaris has initiated its first-in-human clinical trial of PHA121. Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners [...]

Télécharger le fichier pdf





X

X